brexanolone; allopregnanolone (Zulresso)
Jump to navigation
Jump to search
Indications
- post-partum depression[1] (FDA-approved[3])
Dosage
- administered during a 60-hour intravenous infusion
Adverse effects
- risk for loss of consciousness/presyncope (4%)[1]
Mechanism of action
- neuroactive metabolite of progesterone[2]
- barbiturate-like modulator of central GABA receptors
- modifies a range of behaviors, including the stress response
- released in the brain in response to stress,
- quiets the neural system within 30 minutes of escalation
- responsible for the extreme mood swings found in teenagers
More general terms
References
- ↑ Jump up to: 1.0 1.1 1.2 Young K, Young, Sadoughi S, Sofair A. FDA Advisers Vote for Approval of Postpartum Depression Treatment. Physician's First Watch, Nov 5, 2018 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
FDA Briefing Document. Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee Meeting. November 2, 2018 Topic: New Drug Application 211371/New Drug Application, brexanolone for the Treatment of Postpartum Depression https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM624643.pdf - ↑ Jump up to: 2.0 2.1 PubChem: 92786
- ↑ Jump up to: 3.0 3.1 FDA News Release. March 19, 2019 FDA approves first treatment for post-partum depression. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm